Original Research Prim Care Companion CNS Disord February 2022

Triggers and Characteristics of Brain Zaps According to the Findings of an Internet Questionnaire

PCC CNS Disord 2022;24(1):10.4088/PCC.21m02972

Full Article Read the complete peer-reviewed article in Prim Care Companion CNS Disord. Clinical Summary Patients stopping or reducing antidepressants sometimes report “brain zaps,” but these symptoms are often poorly characterized and easy to dismiss. This study gives clinicians concrete features to recognize—including links to antidepressant half-life, eye or head movement triggers, and substantial functional burden—so the complaint can be identified and managed more effectively. FAQ What are brain zaps according to this study?

Key Takeaways Among 2,267 analyzable responses, zap onset latency tracked antidepressant half-life: long half-life agents had longer onset than the other groups, and medium half-life drugs also had longer latency than paroxetine and (des)venlafaxine (P < .0001, χ2 = 144.6). Clinical Guide How can clinicians identify when a patient's brief head sensations are likely antidepressant discontinuation brain zaps? Clinical Guide How should clinicians respond when a patient develops brain zaps during antidepressant discontinuation?